Premium
CC chemokine receptor 5Δ32 polymorphism—a risk factor for ischemic‐type biliary lesions following orthotopic liver transplantation
Author(s) -
Moench Christian,
Uhrig Anja,
Lohse Ansgar W.,
Otto Gerd
Publication year - 2004
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.20095
Subject(s) - medicine , liver transplantation , orthotopic liver transplantation , gastroenterology , risk factor , transplantation
Ischemic‐type biliary lesions are a major complication following orthotopic liver transplantation. They occur in up to 26% of liver transplant recipients. Among other factors, unknown immunologic factors have always been assumed to be partly responsible for these lesions. CC‐chemokines and their receptors play a key role in postoperative immunomodulation after liver transplantation. The non‐function CC‐chemokine receptor 5Δ32 polymorphism (CCR5Δ32) has been shown to lead to a lower rate of acute rejection after kidney transplantation; in liver transplantation the role of CCR5Δ32 is unclear. We investigated the influence of the CCR5Δ32 after liver transplantation with special regard to ischemic‐type biliary lesions. The CC‐chemokine receptor‐5 (CCR5) of 146 recipients was analyzed by polymerase chain reaction to detect CCR5Δ32 in blood samples of patients after liver transplantation. One hundred twenty patients with wild‐type CCR5 and 26 patients with CCR5Δ32 (1 homozygote, 25 heterozygote) were identified. Ischemic‐type biliary lesions occurred in 14 of 120 patients with wild‐type CCR5 and in 8 of 26 patients with CCR5Δ32 polymorphism ( P = = 0.01). 5 year patient survival with CCR5Δ32 and CCR5 was 70% and 85%, respectively ( P = .0067). Our results show that the CCR5Δ32 is a significant risk factor for the development of ischemic‐type biliary lesions after liver transplantation and leads to a reduction in 5‐year survival. In conclusion, the CCR5 status should be screened prospectively before liver transplantation. (Liver Transpl 2004;10:434–439.)